Everything below concerns Tesamorelin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
=== Academic career === Bumpus became a Professor of Medicine in the clinical pharmacology division of Johns Hopkins University School of Medicine, with a secondary appointment in the Department of Pharmacology and Molecular Sciences. She started her own laboratory at Johns Hopkins School of Medicine in 2010 as an Assistant Professor of Medicine and Pharmacology, was promoted to Associate Professor in February 2015, and received Professorship in 2020. Bumpus is known for her research on the metabolism of antiviral drugs used to treat HIV-1 and how genetic variations in drug-processing enzymes may impact these drugs' efficacy. She became Hopkins’ inaugural associate dean of institutional and student equity in 2015 and instituted mentoring programs to expand access to resources and opportunities. After holding that role for two years, in July 2017 she transitioned into a role as senior consulting strategist for Academic and Research Diversity, working with the chief diversity officer to develop and implement diversity and inclusion programs across Johns Hopkins School of Medicine. Bumpus received a Presidential Early Career Award for Scientists and Engineers in 2016. In July 2018, she was named as Associate Dean for Basic Research at Johns Hopkins University School of Medicine.
=== Cyclin dependent kinases === Cyclin dependent kinases (CDKs) are a group of several different kinases involved in regulation of the cell cycle. They phosphorylate other proteins on their serine or threonine residues, but CDKs must first bind to a cyclin protein in order to be active. Different combinations of specific CDKs and cyclins mark different parts of the cell cycle. Additionally, the phosphorylation state of CDKs is also critical to their activity, as they are subject to regulation by other kinases (such as CDK-activating kinase) and phosphatases (such as Cdc25). Once the CDKs are active, they phosphorylate other proteins to change their activity, which leads to events necessary for the next stage of the cell cycle. While they are most known for their function in cell cycle control, CDKs also have roles in transcription, metabolism, and other cellular events. Because of their key role in the controlling cell division, mutations in CDKs are often found in cancerous cells. These mutations lead to uncontrolled growth of the cells, where they are rapidly going through the whole cell cycle repeatedly. CDK mutations can be found in lymphomas, breast cancer, pancreatic tumors, and lung cancer. Therefore, inhibitors of CDK have been developed as treatments for some types of cancer.
The only confirmed isotope of oganesson, 294Og, has much too short a half-life to be chemically investigated experimentally. Therefore, no compounds of oganesson have been synthesized yet. Nevertheless, calculations on theoretical compounds have been performed since 1964. It is expected that if the ionization energy of the element is high enough, it will be difficult to oxidize and therefore, the most common oxidation state would be 0 (as for the noble gases); nevertheless, this appears not to be the case. Calculations on the diatomic molecule Og2 showed a bonding interaction roughly equivalent to that calculated for Hg2, and a dissociation energy of 6 kJ/mol, roughly 4 times of that of Rn2. Most strikingly, it was calculated to have a bond length shorter than in Rn2 by 0.16 Å, which would be indicative of a significant bonding interaction. On the other hand, the compound OgH+ exhibits a dissociation energy (in other words proton affinity of oganesson) that is smaller than that of RnH+. The bonding between oganesson and hydrogen in OgH is predicted to be very weak and can be regarded as a pure van der Waals interaction rather than a true chemical bond. On the other hand, with highly electronegative elements, oganesson seems to form more stable compounds than for example copernicium or flerovium. The stable oxidation states +2 and +4 have been predicted to exist in the fluorides OgF2 and OgF4. The +6 state would be less stable due to the strong binding of the 7p1/2 subshell. This is a result of the same spin–orbit interactions that make oganesson unusually reactive.
Ephedrine and pseudoephedrine are also relative, not absolute, contraindications. They are generally avoided or used only cautiously at reduced doses with monitoring because they may raise blood pressure. Pseudoephedrine is less potent than ephedrine, and ephedrine is less potent than amphetamine. Phenelzine generally does not need to be stopped before surgery solely because anesthesia is planned. Modern guidance states that MAOI treatment should not be discontinued without conferring with the prescribing psychiatrist, because depressive relapse risk may outweigh perioperative interaction risk when anesthetic and analgesic agents are chosen carefully. In perioperative care, the main drugs to avoid are those with significant serotonin reuptake inhibition or serotonin-releasing activity, especially serotonergic opioid analgesics such as meperidine (pethidine) and tramadol. Other opioids listed as serotonergic or uncertain-risk include methadone, tapentadol, dextromethorphan, dextropropoxyphene, pentazocine, and levorphanol. Other perioperative agents requiring avoidance or special caution include pancuronium, a muscle relaxant sometimes used with general anesthetics, and methylene blue, which has clinically relevant MAOI activity itself. These are not avoided because they are serotonin reuptake inhibitors. Direct-acting vasopressors such as epinephrine, norepinephrine, and phenylephrine are not absolute contraindications, but lower initial doses and careful titration are advised because their pressor effects may be potentiated.
Recently, sequence context-specific amino acid similarities have been derived that do not need substitution matrices but that rely on a library of sequence contexts instead. Using this idea, a context-specific extension of the popular BLAST program has been demonstrated to achieve a twofold sensitivity improvement for remotely related sequences over BLAST at similar speeds (CS-BLAST).
Sources: en.wikipedia.org
== Relation to kinetic theory == The kinetic theory of gases relates the macroscopic properties of gases, such as pressure and volume, to the microscopic properties of the molecules which make up the gas, particularly the mass and speed of the molecules. To derive Charles's law from kinetic theory, it is necessary to have a microscopic definition of temperature: this can be conveniently taken as the temperature being proportional to the average kinetic energy of the gas molecules, Ek:
Stress may result from rough handling, washing and immersion in water, or transport (e.g., during shipping), which may in some cases contribute to mortality. Inbreeding depression can result in reduced physical health for farmed insects and producers generally make efforts to maintain a more genetically diverse population. Insects may be fed toxin-contaminated grains or plastics/polymers that may reduce their health, depending on the level of inclusion and specific types of these ingredients used (though this is not expected to be common practice in the industry currently).
=== Medication === If monitoring reveals failing control of glucose levels with these measures, or if there is evidence of complications like excessive fetal growth, treatment with insulin might be necessary. This is most commonly fast-acting insulin given just before eating to blunt glucose rises after meals. Care needs to be taken to avoid low blood sugar levels due to excessive insulin. Insulin therapy can be normal or very tight; more injections can result in better control but require more effort, and there is no consensus that it has large benefits. A 2016 Cochrane review (updated in 2023) concluded that quality evidence is not yet available to determine the best blood sugar range for improving health for pregnant women with GDM and their babies. There is some evidence that certain medications by mouth might be safe in pregnancy, or at least, are less dangerous to the developing fetus than poorly controlled diabetes. When comparing which diabetes tablets (medication by mouth) work best and are safest, there is not enough quality research to support one medication over another. The medication metformin is better than glyburide. If blood glucose cannot be adequately controlled with a single agent, the combination of metformin and insulin may be better than insulin alone. Another review found good short term safety for both the mother and baby with metformin but unclear long term safety. People may prefer metformin by mouth to insulin injections. Treatment of polycystic ovarian syndrome with metformin during pregnancy has been noted to decrease GDM levels.
All human remains at the site were found to contain "very high levels" of mercury. This is believed to be either due to their continuous exposure to mercury-containing cinnabar or because their skin was painted with mercury. Additionally, evidence of osteoarthritis was found in bones, which may indicate that those humans either walked a lot or were dancers.
Sources: en.wikipedia.org
The other two electric utility companies in the country are Sarawak Energy and Sabah Electricity. In 2013, Malaysia's total power generation capacity was over 29,728 megawatts. Total electricity generation was 140,985.01 GWh and total electricity consumption was 116,087.51 GWh. Energy production in Malaysia is largely based on oil and natural gas, owing to Malaysia's oil and natural gas reserves, which are the fourth largest in the Asia-Pacific region.
=== Pharmacokinetics === Bromantane is used clinically in doses of 50 mg to 100 mg per day in the treatment of asthenia. The rate of absorption in women is greater than in men, with maximum blood concentrations being reached at 2.75 and 4 hours after oral administration, respectively. The main metabolite of bromantane is 6β-hydroxybromantane.
This PFS benefit was consistent across subgroups with individual high-risk cytogenetic abnormalities, including patients with del(17p). PFS was also longer with IRd versus placebo- in patients with 1q21 amplification, and in the "expanded high-risk" group, defined as those with high-risk cytogenetic abnormalities and/or 1q21 amplification. IRd demonstrated substantial benefit compared with placebo in relapsed/refractory multiple myeloma patients with high-risk and standard-risk cytogenetics, and improves the poor PFS associated with high-risk cytogenetic abnormalities.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.